Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

PD-1 Inhibitor Combinations As Salvage Therapy for Relapsed/Refractory Multiple Myeloma (MM) Patients Progressing after Bcma-Directed CAR T Cells

Luca Bernabei, Alfred L. Garfall, MD, J. Joseph Melenhorst, PhD, Simon F Lacey, PhD BS, Edward A. Stadtmauer, MD FACP, Dan T. Vogl, MD, Vanessa Gonzalez, Gabriela Plesa, MD, Regina M Young, PhD, Adam Waxman, MD, Bruce L Levine, PhD, Carl H June, MD, Michael C. Milone, MD PhD, Adam D. Cohen, MD

Blood (2018) 132 (Supplement 1): 1973.

https://doi.org/10.1182/blood-2018-99-119514

Published: 2018

Journal Articles

Predictors of T Cell Expansion and Clinical Responses Following B-Cell Maturation Antigen-Specific Chimeric Antigen Receptor T Cell Therapy (CART-BCMA) for Relapsed/Refractory Multiple Myeloma (MM)

Adam D. Cohen, MD, J. Joseph Melenhorst, PhD, Alfred L. Garfall, MD, Simon F Lacey, PhD BS, Megan Davis, PhD, Dan T. Vogl, MD, Lifeng Tian, PhD, Vanessa Gonzalez, Iulian Pruteanu, PhD, Anne Marie Nelson, Gabriela Plesa, MD, Adam Waxman, MD, Regina M Young, PhD, Bruce L Levine, PhD, Carl H June, MD, Edward A. Stadtmauer, MD FACP, Michael C. Milone, MD PhD

Blood (2018) 132 (Supplement 1): 1974.

https://doi.org/10.1182/blood-2018-99-119665

Published: 2018

Journal Articles

Long-Term Remission of CLL Sustained By Pauciclonal Anti-CD19 Chimeric Antigen Receptor T (CTL019) Cell Clones

J. Joseph Melenhorst, PhD, David L. Porter, MD, Lifeng Tian, PhD, Simon F Lacey, PhD BS, Christopher L Nobles, PhD, Joseph A Fraietta, PhD, Noelle V. Frey, MD, Irina Kulikovskaya, Minnal Gupta, Regina M Young, PhD, David E Ambrose, BS, Don L. Siegel, MD PhD, Frederic D Bushman, PhD, Carl H June, MD

Blood (2018) 132 (Supplement 1): 699.

https://doi.org/10.1182/blood-2018-99-117390

Published: 2018

Journal Articles

Sequential Anti-CD19 Directed Chimeric Antigen Receptor Modified T-Cell Therapy (CART19) and PD-1 Blockade with Pembrolizumab in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas

Elise A. Chong, MD, Jakub Svoboda, MD, Sunita Dwivedy Nasta, MD, Daniel J. Landsburg, MD, Nicole Winchell, Ellen Napier, NP, Anthony R. Mato, MD MSCE, J. Joseph Melenhorst, PhD, Marco Ruella, MD, Simon F Lacey, PhD BS, Carl H June, MD, Stephen J. Schuster, MD

Blood (2018) 132 (Supplement 1): 4198.

https://doi.org/10.1182/blood-2018-99-119502

Published: 2018

Journal Articles

Vector Integration and Efficacy of CD19-Directed CAR T Cell Therapy in Acute Lymphoblastic Leukemia (ALL) and Chronic Lymphocytic Leukemia (CLL)

Christopher L Nobles, PhD, John K Everett, Shantan Reddy, Joseph A Fraietta, PhD, David L. Porter, MD, Noelle V. Frey, MD, Stephan A. Grupp, MD PhD, Don L. Siegel, MD PhD, Simon F Lacey, PhD BS, Carl H June, MD, Frederic D Bushman, PhD, J. Joseph Melenhorst, PhD

Blood (2018) 132 (Supplement 1): 4548.

https://doi.org/10.1182/blood-2018-99-117034

Published: 2018

Journal Articles

Checkpoint Inhibitors Augment CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy in Relapsed B-Cell Acute Lymphoblastic Leukemia

Amanda M. Li, MD, George E Hucks, Amanda M. Dinofia, MD, Alix E. Seif, MD, David T Teachey, MD, Diane Baniewicz, Colleen Callahan, Christina Fasano, Beth McBride, Vanessa Gonzalez, Farzana Nazimuddin, MS, David L. Porter, MD, Simon F Lacey, PhD BS, Carl H June, MD, Stephan A. Grupp, MD PhD, Shannon L. Maude, MD PhD

Blood (2018) 132 (Supplement 1): 556.

https://doi.org/10.1182/blood-2018-99-112572

Published: 2018

Journal Articles

Prospective Clinical Trial of Anti-CD19 CAR T Cells in Combination with Ibrutinib for the Treatment of Chronic Lymphocytic Leukemia Shows a High Response Rate

Blood (2018) 132 (Supplement 1): 298.

https://doi.org/10.1182/blood-2018-99-115418

Published: 2018

Journal Articles

Identification of Functional Determinants of Response and Resistance to CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy of Chronic Lymphocytic Leukemia

Blood (2017) 130 (Supplement 1): 3181.

https://doi.org/10.1182/blood.V130.Suppl_1.3181.3181

Published: 2017

Journal Articles

Treating Relapsed / Refractory (RR) AML with Biodegradable Anti-CD123 CAR Modified T Cells

Katherine D Cummins, BMBS, Noelle Frey, MD, Anne Marie Nelson, Aliza Schmidt, MS, Selina Luger, MD FRCPC, Randi E. Isaacs, MD, Simon F Lacey, PhD BS, Elizabeth Hexner, MDMS, J. Joseph Melenhorst, PhD, Carl H June, MD, David L Porter, MD, Saar I Gill, MD PhD

Blood (2017) 130 (Supplement 1): 1359.

https://doi.org/10.1182/blood.V130.Suppl_1.1359.1359

Published: 2017

Journal Articles

Durable Remissions with Humanized CD19-Targeted Chimeric Antigen Receptor (CAR)-Modified T Cells in CAR-Naive and CAR-Exposed Children and Young Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia

Blood (2017) 130 (Supplement 1): 1319.

https://doi.org/10.1182/blood.V130.Suppl_1.1319.1319

Published: 2017

Journal Articles

Clinical Evidence That Deficiency of the Methylcytosine Dioxygenase TET2 Gene Promotes the Clonal Expansion and Therapeutic Efficacy of CD19-Directed T Cells

Blood (2017) 130 (Supplement 1): 1909.

https://doi.org/10.1182/blood.V130.Suppl_1.1909.1909

Published: 2017

Journal Articles

Clinical Efficacy of Anti-CD22 Chimeric Antigen Receptor T Cells for B-Cell Acute Lymphoblastic Leukemia Is Correlated with the Length of the Scfv Linker and Can be Predicted Using Xenograft Models

Marco Ruella, MD, Shannon L Maude, MD PhD, Boris Engels, PhD, David M. Barrett, Noelle Frey, MD, Katherine T Marcucci, PhD, Olga Shestova, PhD, Nathan Singh, MD, Jessica Perazzelli, PhD, David A Christian, PhD, Dana Haagen, BS, Simon F Lacey, PhD BS, J. Joseph Melenhorst, PhD, Jennifer Brogdon, PhD, Regina M Young, PhD, David L Porter, MD, Carl H June, MD, Stephan A Grupp, MD PhD, Saar I. Gill, MD PhD

Blood (2017) 130 (Supplement 1): 807.

https://doi.org/10.1182/blood.V130.Suppl_1.807.807

Published: 2017

Journal Articles

Pilot Study of Non-Viral, RNA-Redirected Autologous Anti-CD19 Chimeric Antigen Receptor Modified T-Cells in Patients with Refractory/Relapsed Hodgkin Lymphoma (HL)

Blood (2017) 130 (Supplement 1): 653.

https://doi.org/10.1182/blood.V130.Suppl_1.653.653

Published: 2017

Journal Articles

Novel Correlation between B Cell Survival Cytokines and Inhibitors in Hemophilia A

Bhavya S Doshi, MD, Simon F Lacey, PhD BS, Fang Chen, PhD, Leslie J Raffini, MD MSCE, Valder R Arruda, MD PhD

Blood (2017) 130 (Supplement 1): 3677.

https://doi.org/10.1182/blood.V130.Suppl_1.3677.3677

Published: 2017

Journal Articles

A Cellular Antidote to Specifically Deplete Anti-CD19 Chimeric Antigen Receptor (CAR19) Positive Cells

Marco Ruella, MD, David M. Barrett, Olga Shestova, PhD, Jessica Perazzelli, PhD, Avery D. Posey, PhD, Miroslaw Kozlowski, PhD, Simon F Lacey, PhD BS, J. Joseph Melenhorst, PhD, Carl H June, MD, Saar I. Gill, MD PhD

Blood (2017) 130 (Supplement 1): 4463.

https://doi.org/10.1182/blood.V130.Suppl_1.4463.4463

Published: 2017

Journal Articles

Phase I/II Study of Pembrolizumab for Progressive Diffuse Large B Cell Lymphoma after Anti-CD19 Directed Chimeric Antigen Receptor Modified T Cell Therapy

Elise A. Chong, MD, J. Joseph Melenhorst, PhD, Jakub Svoboda, MD, Sunita Dwivedy Nasta, MD, Daniel J. Landsburg, MD, Anthony R. Mato, MD, Lifeng Tian, PhD, Harit Parakandi, Simon F Lacey, PhD BS, Carl H June, MD, Stephen J. Schuster, MD

Blood (2017) 130 (Supplement 1): 4121.

https://doi.org/10.1182/blood.V130.Suppl_1.4121.4121

Published: 2017

Journal Articles

Safety and Efficacy of B-Cell Maturation Antigen (BCMA)-Specific Chimeric Antigen Receptor T Cells (CART-BCMA) with Cyclophosphamide Conditioning for Refractory Multiple Myeloma (MM)

Blood (2017) 130 (Supplement 1): 505.

https://doi.org/10.1182/blood.V130.Suppl_1.505.505

Published: 2017

Journal Articles

Efficient Trafficking of Chimeric Antigen Receptor (CAR)-Modified T Cells to CSF and Induction of Durable CNS Remissions in Children with CNS/Combined Relapsed/Refractory ALL

Susan R. Rheingold, MD, Lanyi Nora Chen, BS, Shannon L Maude, MD PhD, Richard Aplenc, MD PhD, Christine Barker, BS, David M. Barrett, MD PhD, Colleen Callahan, MSN, Katherine Cebry, Irina Kulikovskaya, PhD, Simon F. Lacey, PhD BS, Bruce L. Levine, PhD, Jan J. Melenhorst, PhD, Pamela A Shaw, PhD, Anna Sparrow, David T Teachey, MD, Mark Duckworth, BS, Carl H. June, MD, Stephan A. Grupp, MD PhD

Blood (2015) 126 (23): 3769.

https://doi.org/10.1182/blood.V126.23.3769.3769

Published: 2015

Journal Articles

Durable Remissions in Children with Relapsed/Refractory ALL Treated with T Cells Engineered with a CD19-Targeted Chimeric Antigen Receptor (CTL019)

Stephan A. Grupp, MD PhD, Shannon L Maude, MD PhD, Pamela A Shaw, PhD, Richard Aplenc, MD PhD, David M. Barrett, MD PhD, Colleen Callahan, MSN, Simon F. Lacey, PhD BS, Bruce L. Levine, PhD, J Joseph Melenhorst, PhD, Laura Motley, RN, Susan R. Rheingold, MD, David T Teachey, MD, Patricia A. Wood, MD PhD, David Porter, MD, Carl H. June, MD

Blood (2015) 126 (23): 681.

https://doi.org/10.1182/blood.V126.23.681.681

Published: 2015

Journal Articles

Efficacy and Safety of Humanized Chimeric Antigen Receptor (CAR)-Modified T Cells Targeting CD19 in Children with Relapsed/Refractory ALL

Blood (2015) 126 (23): 683.

https://doi.org/10.1182/blood.V126.23.683.683

Published: 2015

NARROW

PD-1 Inhibitor Combinations As Salvage Therapy for Relapsed/Refractory Multiple Myeloma (MM) Patients Progressing after Bcma-Directed CAR T Cells

Predictors of T Cell Expansion and Clinical Responses Following B-Cell Maturation Antigen-Specific Chimeric Antigen Receptor T Cell Therapy (CART-BCMA) for Relapsed/Refractory Multiple Myeloma (MM)

Long-Term Remission of CLL Sustained By Pauciclonal Anti-CD19 Chimeric Antigen Receptor T (CTL019) Cell Clones

Sequential Anti-CD19 Directed Chimeric Antigen Receptor Modified T-Cell Therapy (CART19) and PD-1 Blockade with Pembrolizumab in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas

Vector Integration and Efficacy of CD19-Directed CAR T Cell Therapy in Acute Lymphoblastic Leukemia (ALL) and Chronic Lymphocytic Leukemia (CLL)

Checkpoint Inhibitors Augment CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy in Relapsed B-Cell Acute Lymphoblastic Leukemia

Prospective Clinical Trial of Anti-CD19 CAR T Cells in Combination with Ibrutinib for the Treatment of Chronic Lymphocytic Leukemia Shows a High Response Rate

Identification of Functional Determinants of Response and Resistance to CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy of Chronic Lymphocytic Leukemia

Treating Relapsed / Refractory (RR) AML with Biodegradable Anti-CD123 CAR Modified T Cells

Durable Remissions with Humanized CD19-Targeted Chimeric Antigen Receptor (CAR)-Modified T Cells in CAR-Naive and CAR-Exposed Children and Young Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia

Clinical Evidence That Deficiency of the Methylcytosine Dioxygenase TET2 Gene Promotes the Clonal Expansion and Therapeutic Efficacy of CD19-Directed T Cells

Clinical Efficacy of Anti-CD22 Chimeric Antigen Receptor T Cells for B-Cell Acute Lymphoblastic Leukemia Is Correlated with the Length of the Scfv Linker and Can be Predicted Using Xenograft Models

Pilot Study of Non-Viral, RNA-Redirected Autologous Anti-CD19 Chimeric Antigen Receptor Modified T-Cells in Patients with Refractory/Relapsed Hodgkin Lymphoma (HL)

Novel Correlation between B Cell Survival Cytokines and Inhibitors in Hemophilia A

A Cellular Antidote to Specifically Deplete Anti-CD19 Chimeric Antigen Receptor (CAR19) Positive Cells

Phase I/II Study of Pembrolizumab for Progressive Diffuse Large B Cell Lymphoma after Anti-CD19 Directed Chimeric Antigen Receptor Modified T Cell Therapy

Safety and Efficacy of B-Cell Maturation Antigen (BCMA)-Specific Chimeric Antigen Receptor T Cells (CART-BCMA) with Cyclophosphamide Conditioning for Refractory Multiple Myeloma (MM)

Efficient Trafficking of Chimeric Antigen Receptor (CAR)-Modified T Cells to CSF and Induction of Durable CNS Remissions in Children with CNS/Combined Relapsed/Refractory ALL

Durable Remissions in Children with Relapsed/Refractory ALL Treated with T Cells Engineered with a CD19-Targeted Chimeric Antigen Receptor (CTL019)

Efficacy and Safety of Humanized Chimeric Antigen Receptor (CAR)-Modified T Cells Targeting CD19 in Children with Relapsed/Refractory ALL

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only